When depression has not improved enough with standard medication, the question is rarely whether you have tried hard enough. It is whether a different treatment approach may better fit your symptoms, health history, and daily life. Comparing Spravato versus TMS treatment can help you have a more informed conversation with a psychiatric provider – without assuming there is one right answer for everyone.

Both treatments are used for adults with difficult-to-treat depression, and both can be meaningful next steps when antidepressants alone have not brought adequate relief. They work very differently, involve different schedules, and come with distinct considerations for safety, transportation, insurance, and personal preference.

How Spravato works

Spravato is the brand name for esketamine, a prescription nasal spray administered in a certified health care setting. It is related to ketamine but is a distinct, FDA-approved medication with a specific treatment process and monitoring requirements.

Traditional antidepressants commonly affect serotonin, norepinephrine, or dopamine systems. Spravato works primarily through the brain’s glutamate system. For some people with treatment-resistant depression, this different mechanism may offer symptom improvement when several prior medication approaches have not been enough.

A Spravato appointment is not simply a quick nasal spray visit. Patients self-administer the medication under clinical supervision and remain at the office for monitoring, generally for at least two hours. A provider watches for sedation, dissociation, blood pressure changes, and other side effects before the patient leaves. Because alertness and coordination can be affected, patients need dependable transportation home and should not drive or operate machinery until the following day after a restful sleep.

Treatment typically begins with more frequent visits and may move to a maintenance schedule based on response and the prescribing clinician’s recommendation. Spravato is often considered for adults with treatment-resistant depression, meaning depression that has not responded adequately to multiple antidepressant trials. It may also be considered in other FDA-approved clinical circumstances, as determined by a qualified prescriber.

How TMS treatment works

Transcranial Magnetic Stimulation, or TMS, is a noninvasive treatment that uses magnetic pulses to stimulate targeted areas of the brain involved in mood regulation. During a session, a clinician positions a treatment device against the scalp. The patient remains awake, seated, and able to return to normal activities afterward.

TMS does not involve anesthesia, surgery, or medication entering the bloodstream. A typical course includes brief outpatient sessions on weekdays for several weeks, though the exact schedule depends on the protocol and individual treatment plan. Some newer protocols may use different session lengths or timelines.

Many patients describe a tapping sensation on the scalp during treatment. The most common side effects are temporary scalp discomfort or headache, particularly early in the course. Serious side effects are uncommon, but a seizure is a rare potential risk. Your provider will review your medical history, medications, and any factors that could affect safety before recommending TMS.

TMS is FDA-cleared for certain depressive disorders and may be an option for people who have not had sufficient improvement with medication, cannot tolerate medication side effects, or want a non-medication intervention as part of a broader care plan.

Spravato versus TMS treatment: the practical differences

The biggest distinction is the type of treatment. Spravato is a medication-based intervention with monitored dosing and recovery time at the clinic. TMS is a device-based intervention that targets specific brain circuits through magnetic stimulation and generally allows patients to drive themselves and resume their day after appointments.

The time commitment looks different, too. Spravato visits tend to be longer because of required observation, while TMS sessions are usually shorter but occur more frequently during an initial treatment course. Someone balancing work, school, child care, or a long drive across the Phoenix area may find one schedule more manageable than the other.

Side effect profiles also differ. With Spravato, some patients experience dizziness, nausea, sleepiness, a temporary rise in blood pressure, or dissociation – a feeling of being detached from thoughts, surroundings, or the body. These effects are why in-clinic monitoring is required. With TMS, physical discomfort at the treatment site and headaches are more common concerns. Neither option should be chosen based on convenience alone, but logistics are a legitimate part of personalized care.

Response can differ as well. Some people notice changes relatively early with Spravato, while others need time and ongoing treatment to assess benefit. TMS is generally delivered as a full course, and improvement may build gradually over several weeks. Neither treatment promises a specific outcome, and neither replaces the value of regular follow-up with a psychiatric provider.

Which treatment may fit your situation?

A thorough evaluation should guide the decision. Your clinician will consider your diagnosis, past medication trials, current medications, medical conditions, symptom severity, substance use history, seizure risk, blood pressure, and whether you can safely arrange transportation and attend appointments consistently.

Spravato may be worth discussing if you have treatment-resistant depression and are comfortable with a medication approach that requires monitored office visits. It can be especially relevant for patients whose providers believe a glutamate-focused treatment is clinically appropriate.

TMS may be appealing if you want a noninvasive treatment that does not require sedation or post-visit observation. It may also be a practical choice for someone who can attend frequent short appointments but needs to drive, work, attend classes, or care for family afterward.

There are also situations where the answer is not an either-or decision. Depression treatment often includes several coordinated supports: medication management, psychotherapy, sleep and routine changes, and treatments such as TMS or Spravato when indicated. Cognitive behavioral therapy, trauma-focused therapy, or other evidence-based approaches can help patients build skills alongside interventional treatment.

Questions to bring to your psychiatric appointment

Rather than asking which treatment is “better,” ask which treatment is most appropriate for your depression and circumstances. Useful questions include whether you meet clinical criteria, what prior treatments are needed for insurance authorization, what side effects deserve special attention, and how progress will be measured.

It also helps to ask what happens if the first approach does not provide enough relief. A strong treatment plan includes regular symptom tracking, clear follow-up, and room to adjust the plan when needed. Insurance coverage varies by plan and medical necessity requirements, so a care team can help clarify expected authorization steps and out-of-pocket considerations before treatment begins.

At Strategies for Success, patients can discuss advanced depression treatment alongside therapy and psychiatric care, allowing the plan to reflect the whole person rather than a single symptom score.

Depression can make every decision feel heavier than it should. You do not have to decide between Spravato and TMS on your own. A thoughtful evaluation can turn a confusing comparison into a realistic next step toward measurable symptom improvement and a life that feels more manageable.